Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29200234 | 0.76 | MAOB (0.49) | MAOBMAOARAB9ANPC1ADRA2A | |
| SCHEMBL38628 | 0.75 | MAOB (0.51) | MAOBMAOARAB9ANPC1ADRA2A | |
| SCHEMBL5614890 | 0.75 | TOP2A (0.53) | RAB9ANPC1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL4623912 | 0.75 | METAP2 (0.35) | NPC1METAP2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL6489268 | 0.73 | BCHE (0.40) | RAB9ANPC1METAP2KDM4EALDH1A1 | |
| SCHEMBL38673 | 0.72 | RAB9A (0.48) | RAB9ANPC1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL1377576 | 0.72 | MAOB (0.48) | MAOBMAOARAB9ANPC1ADRA2A | |
| SCHEMBL2203414 | 0.72 | MAOB (0.48) | MAOBMAOARAB9ANPC1ADRA2A | |
| SCHEMBL9110854 | 0.72 | ALDH1A1 (0.36) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL12854020 | 0.71 | MAOB (0.71) | MAOBMAOARAB9ANPC1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318555-B1 | BIFUNCTIONAL CHELATING AGENTS | BWXT MEDICAL LTD (CA) | 2023-08-16 | — | — | EP | disclosed |
| WO-2021059017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | WO | disclosed |
| EP-3318555-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2018-05-09 | — | — | EP | disclosed |
| EP-2536691-B1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-11-22 | — | — | EP | disclosed |
| US-8772446-B2 | Bifunctional chelating agents | NORDION (CANADA) INC. (CA) | 2014-07-08 | — | — | US | disclosed |
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| EP-2536691-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011100829-A1 | BIFUNCTIONAL CHELATING AGENTS | NORDION (CANADA) INC. (CA) | 2011-08-25 | — | — | WO | disclosed |
| EP-2027104-B1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| EP-2079693-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-2027104-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008052899-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| EP-1846363-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007051735-A1 | ARYLSULFONYLCHROMANS AS 5-HT6 INHIBITORS INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006074244-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
| US-6936712-B1 | Process for the production of oxabispidines | ASTRAZENECA AB (SE) | 2005-08-30 | — | — | US | disclosed |
| US-5904739-A | Storage-stable liquid brightener formulations | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-05-18 | — | — | US | disclosed |
| EP-0765964-A2 | Storage stable liquid formulations containing optical brighteners | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313130-A1 | BIFUNCTIONAL CHELATING AGENTS | FCGRT, C1QBP, H1-2 | MAOB 1145/4885MAOA 1469/4885RAB9A 1342/4885 |
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | MAOB 483/4885MAOA 186/4885RAB9A 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.